Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. Multiple lines of evidence suggest that genetic factors are involved in MM pathogenesis, and several studies have identified single nucleotide polymorphisms (SNPs) associated with the susceptibility to the disease. SNPs within miRNA-binding sites in target genes (miRSNPs) may alter the strength of miRNA-mRNA interactions, thus deregulating protein expression. MiRSNPs are known to be associated with risk of various types of cancer, but they have never been investigated in MM. We performed an in silico genome-wide search for miRSNPs predicted to alter binding of miRNAs to their target sequences. We selected 12 miRSNPs and tested their association with MM risk. Our study population consisted of 1,832 controls and 2,894 MM cases recruited from seven European countries and Israel in the context of the IMMEnSE (International Multiple Myeloma rESEarch) consortium. In this population two SNPs showed an association with p < 0.05: rs286595 (located in gene MRLP22) and rs14191881 (located in gene TCF19). Results from IMMEnSE were meta-analyzed with data from a previously published genome-wide association study (GWAS). The SNPs rs13409 (located in the 3 0 UTR of the POU5F1 gene), rs1419881 (TCF19), rs1049633, rs1049623 (both in DDR1) showed significant associations with MM risk. In conclusion, we sought to identify genetic polymorphisms associated with MM risk starting from genome-wide prediction of miRSNPs. For some mirSNPs, we have shown promising associations with MM risk.
Multiple myeloma (MM) is a malignancy of plasma cells, usually infiltrating the bone marrow, and associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. MM affects the places where bone marrow is normally active in an adult. MM is a relatively infrequent cancer among both sexes. On a worldwide scale, it is estimated that about 86,000 incident cases occur annually, accounting for about 0.8% of all new cancer cases. About 63,000 subjects are reported to die from the disease each year, accounting for 0.9% of all cancer deaths and nearly 10% of all hematological neoplastic diseases. Several factors are known or suspected to cause myeloma or trigger an already abnormal or damaged pre-myeloma cell population in the bone marrow. Exposure to toxic chemicals, ionizing radiations, immunodeficiency or infection with cancer-causing viruses have all been implicated as causes or triggers of MM. 1 Converging evidence of MM in monozygotic twins and familial aggregation of MM strongly suggest that What's new? Even though deregulation of miRNA expression has been associated with human cancers little information is available regarding their relation with MM susceptibility. We performed an in silico genome-wide search for miRSNPs and selected the most promising ones for an association study. The SNPs with the strongest associations with MM risk are localized in genes which have never been related with MM.
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MM aetiology has a robust genetic component as well. 2 Several risk loci have been proposed and a few have been identified through candidate gene and genome-wide association studies (GWAS).
3-10 Some of these loci are involved in complex pathways related to cell cycle, cell proliferation and DNA repair, in which micro-RNAs (miRNAs) have a proven regulatory role.
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MiRNAs are small non-coding RNA molecules, 20-25 nucleotides long, highly conserved throughout evolution. In mammals, miRNAs are predicted to control the activity of >60% of all protein-coding genes and participate in the regulation of almost every cellular process investigated to date. 12 They play a major role in post-transcriptional regulation processes, mainly silencing target mRNAs and thus decreasing their corresponding protein expression. 13 These small RNAs post-transcriptionally repress gene expression by recognizing complementary target sites most often in the 3 0 untranslated region (UTR) of target messenger RNAs (mRNAs). Several miRNAs were found to be directly involved in human cancers, including lung, breast, brain, liver, colon cancer and leukemia. In addition, some miRNAs may function as oncogenes or tumor suppressors in tumor development. Furthermore, a widespread down-regulation of miRNAs is commonly observed in human cancers, which promotes cellular transformation and tumorigenesis. [14] [15] [16] [17] Recent studies have revealed a role of miRNAs in MM. Deregulated miRNA expression in plasma cells has been associated with tumor progression, molecular subtypes, clinical staging, prognosis and drug response in MM. 18 Although mutation in miRNA seed sequence seems to be a rare event, sequence variation in miRNA target sites is relatively frequent and may play a role in cancer etiology. In silico analyses of expressed sequence tag SNP databases indicate different allele frequencies of miRNA-binding sites in tumors versus normal tissues. 19 Polymorphisms in miRNA-binding sites in target genes may alter the strength of miRNA-mRNA interactions, thus deregulating protein expression. SNPs belonging to this category are called miRSNPs. 20 MiRSNPs have been shown to be associated with the risk of several cancers. 19, 21, 22 We hypothesize that miRSNPs may have a role in the susceptibility of MM. To this aim, we performed an in silico genome-wide search of miRSNPs predicted to affect binding of micro-RNAs to their target genes and tested the most promising ones in a case-control association study.
Material and Methods

Study population
The study population consisted of 1,832 controls and 2,894 MM cases recruited from seven European countries and Israel in the context of the IMMEnSE (International Multiple Myeloma rESEarch) consortium (Table 1) . 23 Diagnosis of patients with symptomatic MM was performed by hematologists according to the International Myeloma Working Group (IMWG) criteria. Demographic and clinicopathological characteristics including age, gender, country of origin, disease stage (Durie-Salmon and/or International Staging System) and serum creatinine levels were retrospectively gathered from medical records in each participant institution.
Controls were selected among the general population (Italian), blood donors (Danish, Spanish, Polish, Portuguese and French) and hospitalized subjects with different diagnoses excluding cancer (Hungarian and Spanish). Gender and age at recruitment were collected for every subject enrolled. Cases and controls are not matched individually but age distribution and sex ratio were similar between cases and controls ( Table 1) . Control samples have been collected in the same centers of the cases, or at least in the same geographic areas.
In keeping with the guidelines of the Declaration of Helsinki, written informed consent was obtained from each participant and approval for collection and use of the samples was obtained from local Institutional Review Boards. Putative miRNA-binding sites within the 3 0 UTR (defined as transcribed sequences from the stop codon to the end of the last exon of each gene) were detected by jSNPSelector version 1.0.1.7 (http://sourceforge.net/projects/jsnpselector/), a custom-made algorithm that interrogates the ENSEMBL database. The conservation score is assigned to each nucleotide in a multiple species alignment to determine how conserved the nucleotide is.
The strength of binding with the major and the minor allele was measured in silico using the publicly available mrSNP software (http://mrsnp.osu.edu). mrSNP showed a good performance to predict SNPs experimentally validated to affect miRNA binding, correctly identifying 69% (11/16) of the SNPs disrupting binding. 24 The selection with the mentioned workflow resulted in a list of 394 SNPs with high difference in Gibbs free energy between the two alleles (DDG) (Supporting Information  Table S1 ). For mirSNPs predicted to bind more than one miRNA, we summed up all the DDGs for each miRNA, obtaining thus a total DDG.
As a final step, we verified if these miRSNPs were associated with MM risk in a previously published GWAS dataset. 4, 6 Based on the process described above, we started from 2,817 SNPs, and we finally selected 12 SNPs reported in Table 2 . The final list included three SNPs (rs1050239, rs735794 and rs1052536) with highest predicted difference between the two alleles in the strength of binding between miRNAs and their target sequence (total DDG), regardless of association in the previously performed GWAS, with a threshold of total DDG > 550 (another SNP, rs13505, had DDG > 550 as shown in Supporting Information Table S1 , but it could not be designed as TaqMan assay and was therefore excluded). Three more SNPs (rs1803275, rs12509103 .
Statistical analysis
Analysis of association between SNPs and MM risk was performed with multivariate logistic regression models, adjusting for a set of covariates including age (at diagnosis for MM cases, at recruitment for controls), gender and country of origin. The association between miRSNPs and MM risk was calculated by estimating odds ratios (OR) and their 95% confidence intervals (CI). For all genotypes, we performed a statistical analysis with the allelic, dominant, codominant and recessive models. As three of our SNPs (rs1049633, rs1049628 and rs1049623) were located in the same gene DDR1 (r 2 ranging from 0.377 to 0.237 in Caucasians) and two more SNPs (rs1419881 and rs13409) are physically close to each other (r 2 5 0.887), we calculated also M EFF correction. M EFF is a simple correction for multiple testing of SNPs in linkage disequilibrium (LD) with each other, based on the spectral decomposition of matrices of pairwise LD between SNPs. 26 This method provides a useful alternative to more computationally intensive permutation tests. For performing this correction we used an interface available online (http://gump.qimr.edu.au/general/daleN/SNPSpD). We found a M EFF 5 11.50.
A p-value below 0.001, calculated with the formula 0.05/ (11.5 3 4) was considered as threshold of statistical significance, considering the Bonferroni correction for MEFF and the number of inheritance models tested.
Finally, we performed a meta-analysis between the data obtained in IMMEnSE and the data from two GWAS, respectively, conducted in German and English populations. 4, 6 We considered the different countries participating in IMMEnSE and in the GWAS as separate groups and performed metaanalyses according to the fixed effects model.
All the statistical analyses were performed using STATA software, version 11 for Windows.
Results
IMMeNSE
As showed in Table 3 , we did not find strong associations between SNPs and MM risk. Table 3 reports the results of the analyses performed according to an allelic and codominant inheritance model. Two SNPs showed p-values < 0.05: rs286595 (located in gene MRLP22) and rs14191881 (located in gene TCF19). Analyses of recessive and dominant models did not show any association at the level of 0.05 or below (data not shown). For all the analyses none of the SNPs passed the threshold of significance after correction for multiple testing.
Meta-analysis
We performed a meta-analysis between the results from IMMEnSE and the published data of two GWASs conducted in the English and the German populations, respectively, for a total of 1,675 MM cases and 5,903 controls. Complete results are shown in Supporting Information Table S2 . We found pvalues <10 23 for the SNPs rs13409, rs1049623, rs1049633 and rs1419881 according to allelic or co-dominant model and no or minor heterogeneity, suggesting an association with a decreased risk of MM (Table 4) .
Discussion and Conclusion
The first steps of our study were the selection of the SNPs and the genotyping of cases and controls in the context of the IMMEnSE consortium. Although the sample size was adequate, none of the statistical analyses passed the significance threshold after the correction for multiple testing. However SNPs rs286595 (MRPL22) and rs14191881 (TCF19) showed a p values < 0.05. The latter came up also in the meta-analysis, as did the SNPs rs1049633, rs1049623 (both located in the 3'UTR of the DDR1) and rs13409 (POU1F5), which all showed an association with a decreased risk of MM, with no heterogeneity between IMMEnSE and the GWAS except for one case (rs1049633, p heterogeneity 5 0.038). The protein encoded by the gene DDR1 belongs to a subfamily of tyrosine kinase receptors that are activated by various types of collagen. Upregulation of DDR1 in multiple human cancers implies that DDR1 is involved in tumor progression. [27] [28] [29] Four different miRNAs are predicted to bind DDR1 at the location of rs1049633: miR-2355-3p, miR-7, miR-3915 and miR-4689. When A substitutes G, miR-2355-3p and miR-4689 are predicted to bind more tightly to the DDR1 3'UTR, instead, for miR-7 and miR-3915 the A allele is predicted to decrease its binding affinity. MicroRNA-7 (miR-7) acts as a potential tumor suppressor, but the opposite effect also has been reported. 30 MiR-7 regulates diverse fundamental biological processes of cancer cells including initiation, proliferation, migration, invasion, survival and death Table 3 . Results of the case/control study in IMMeNSE 
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by targeting a number of oncogenic signaling pathways. Two miRNAs are predicted to bind the DDR1 gene where the SNP rs1049623 is located: miR-4499 and miR-4513. We found out that carriers of C allele show a decreased risk of MM. The binding force of miRNAs for this SNP is predicted to be stronger when this allele is present, therefore it may be that when a C is present DDR1 is down-regulated, whereas usually this gene is upregulated in cancer. 31 Thus, the association we observed is consistent with the known biological function of DDR1. SNP rs1419881 is located in the gene TCF19 (transcription factor 19), which encodes a protein containing a PHD-type zinc finger domain and likely functions as a transcription factor. TCF19 was found to be involved in cell cycle progression and proliferation in the pancreatic b-cell and it plays a role in the pathogenesis of diabetes. 32 Type 2 diabetes has been frequently associated with MM and it is thought to influence the myelomagenesis through hyperglycemia and insulin-dependent and -independent mechanisms. 33 Moreover, rs1419881 is in linkage disequilibrium (r 2 5 0.82) with the SNP rs3130453 which is located in the gene CCHCR, also known as HCR (Supporting Information Table S2 ). The detailed function of the gene remains largely unknown. In particular, rs3130453 creates either a codon for tryptophan (G) or a stop codon (A). The stop codon (allele Iso3) results in the shorter isoform whereas the codon for tryptophan enables the usage of an earlier translation start site in exon 1b, thus leading to a protein with 89 additional amino acids in its N-terminal domain. 34 The most significant association in our analyses was found in the codominant model (p 5 0.0002), where carriers of AA genotype have a decreased risk of MM.
The gene POU5F1, where rs13409 is located, encodes a transcription factor containing a POU homeodomain that plays a key role in embryonic development and stem cell pluripotency. Interestingly, POU5F1 is also named as OCT-4 and it is one of the four main factors involved in the formation of the induced pluripotent stem cells. 35 It has a pivotal role in the maintenance of the differentiation status of, in practice, all types of cells and its regulation could be very important also for maintaining the appropriate differential state in B lymphocytes.
Our study has several strengths: large sample size and systematic, genome-wide search for miRSNPs. The genome-wide approach ensures that the whole set of common miRSNPs has been considered for our study. We cannot exclude that rarer miRSNPs have a role in MM risk, but a much larger sample size would be needed to address this issue.
Predictions of miRNA-mRNA binding were performed only with in silico tools and not experimentally confirmed. This could be a weakness of the study. Moreover, the vast majority of study subjects were Caucasians, thus it is not clear if these results can be generalized to other populations as well. Finally, the associations were largely driven by the German component of the GWAS results, and were weaker in IMMEnSE and in the English GWAS. Indeed, when the German population is excluded from the meta-analysis none of the SNPs were significantly associated with MM risk considering a Bonferroni-corrected threshold, although rs286595 was associated with p < 0.05 (Supporting Information Table S3 ). Thus, the results of the meta-analysis should be taken with caution. However, we did not observe statistically significant heterogeneity among the IMMEnSE subgroups and the GWAS populations (except for rs1049633, p heterogeneity 5 0.038).
In conclusion, we found promising associations between mirSNPs in DDR1, TCF19, POU5F1 and MM risk, which should be further replicated in independent studies. If these associations are confirmed, it would be interesting to test the function of the SNPs with in vitro and in vivo studies.
